19 assets in Neuromyelitis Optica

Therapeutic assets addressing Neuromyelitis Optica, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Neuromyelitis Optica	Fred Hutchinson Cancer Center	P2	CCC (53)
Camustine Neuromyelitis Optica	Fred Hutchinson Cancer Center	P2	CCC (53)
Cytarabine Neuromyelitis Optica	Fred Hutchinson Cancer Center	P2	CCC (53)
Etoposide Neuromyelitis Optica	Fred Hutchinson Cancer Center	P2	CCC (53)
Melphalan Neuromyelitis Optica	Fred Hutchinson Cancer Center	P2	CCC (53)
Prednisone Neuromyelitis Optica	Fred Hutchinson Cancer Center	P2	CCC (53)
Cyclophosphamide Neuromyelitis Optica	Tongji Hospital	P1	CCC (50)
Fludarabine Neuromyelitis Optica	Tongji Hospital	P1	CCC (50)
hbi0101 cart Neuromyelitis Optica	Polina Stepensky	P1	CC (43)
Lcar-Aio T Cells Neuromyelitis Optica	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1	CC (43)
Universal Cd19 Car-Γδt Cell Neuromyelitis Optica	Tongji Hospital	P1	CC (43)
ct103a cells Neuromyelitis Optica	Tongji Hospital	Early P1	C (39)
qt-019c Neuromyelitis Optica	Tianjin Huanhu Hospital	Early P1	C (39)
Ucar T-Cell Neuromyelitis Optica	Tianjin Huanhu Hospital	Early P1	C (39)
Universal Bcma Car-T Neuromyelitis Optica	Xuanwu Hospital, Beijing	Early P1	C (39)
Universal Cd19 Car-T Neuromyelitis Optica	Xuanwu Hospital, Beijing	Early P1	C (39)
Calculus Bovis Sativus Neuromyelitis Optica	Tongji Hospital	N/A	D (30)
lp-168 Neuromyelitis Optica	Guangzhou Lupeng Pharmaceutical Company LTD.	P1	NR ()